Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Exploratory Study of αPD1-MSLN-CAR T Cells Secreting PD-1 Nanobodies for the Treatment of MSLN-positive Advanced Solid Tumors

X
Trial Profile

An Exploratory Study of αPD1-MSLN-CAR T Cells Secreting PD-1 Nanobodies for the Treatment of MSLN-positive Advanced Solid Tumors

Status: Recruiting
Phase of Trial: Phase 0

Latest Information Update: 23 May 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Autologus mesothelin targetted CAR-T cell therapy-Shanghai Cell Therapy Group (Primary) ; Cyclophosphamide; Fludarabine
  • Indications Cholangiocarcinoma; Colorectal cancer; Malignant-mesothelioma; Ovarian cancer; Peritoneal cancer; Solid tumours
  • Focus Adverse reactions
  • Sponsors Shanghai Cell Therapy Group
  • Most Recent Events

    • 19 Apr 2023 Results (n=11; From July 20, 2020 to December 31, 2022) assessing the safety and efficacy of BZDS1901in treatment of malignant mesothelioma, presented at the 114th Annual Meeting of the American Association for Cancer Research.
    • 10 Aug 2020 New trial record
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top